Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. (Q38184587)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

Soluble epoxide hydrolase

7 March 2020

main subject

cardiovascular disease

1 reference

based on heuristic

inferred from title

0 references

author

Dominique Guerrot

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Dominique Guerrot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1

Thomas Duflot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Clothilde Roche

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Fabien Lamoureux

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jeremy Bellien

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

4 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

229-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxides and soluble epoxide hydrolase in cardiovascular physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Red blood cells: reservoirs of cis- and trans-epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential C6 channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Cyclic AMP-dependent modulation of cardiac L-type Ca2+ and transient outward K+ channel activities by epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

cDNA cloning and expression of a soluble epoxide hydrolase from human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Mammalian epoxide hydrolases in xenobiotic metabolism and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

The Protein Data Bank: a computer-based archival file for macromolecular structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase dimerization is required for hydrolase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Expression and regulation of soluble epoxide hydrolase in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Distribution and expression of soluble epoxide hydrolase in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Leukotoxin-diol: a putative toxic mediator involved in acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Genetic and environmental factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Polymorphisms in human soluble epoxide hydrolase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase: gene structure, expression and deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Potent urea and carbamate inhibitors of soluble epoxide hydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition of cytosolic epoxide hydrolase by trans-3-phenylglycidols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Structural refinement of inhibitors of urea-based soluble epoxide hydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Synthesis and biological activity of 4-substituted benzoxazolone derivatives as a new class of sEH inhibitors with high anti-inflammatory activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase is a therapeutic target for acute inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

21 January 2018

EET signaling in cancer

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

Orally bioavailable potent soluble epoxide hydrolase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.881354

10.1517/17460441.2014.881354

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490654%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference